The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Mohamad MohtyThe Multiple Myeloma Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, How to treat advanced refractory multiple myeloma (MM)?
How to treat advanced refractory MM?
Mohty begins by discussing some of the latest novel and investigational therapies for the treatment of advanced refractory disease. He highlights bispecific antibodies and CAR T-cell therapies, sharing some of their latest safety and efficacy data, as well as the potential future indication for CAR T-cell therapy in earlier lines based on the results of CARTITUDE-4.
Mohty concludes with a summary of the management strategies for the neurotoxicity and infection rates associated with these treatments, emphasizing monitoring and prophylaxis as key.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content